BackNeogenomics Overview

Neogenomics Inventory

Track Neogenomics's inventory ($27M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Inventory
$27.14M
↓ 20.58% YoYΔ $-7.03M vs prior year quarter

Peer average / median

Loading

Neogenomics Inventory History

Loading

Neogenomics vs. peers: Inventory Comparison

Loading

Neogenomics Inventory Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Neogenomics (NEO) FAQ

As of the most recent data (June 2026), NEO shows a inventory of $27M. That compares with $34M in the prior-year period — down 20.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NEO's inventory is now $27M (was $34M) — a 20.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Neogenomics is outperforming or lagging.

Tracking NEO's inventory over time shows whether Neogenomics is scaling, shrinking, or reshaping that part of the business. The current reading is $27M That compares with $34M in the prior-year period — down 20.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this inventory page, Stockcircle has Neogenomics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect inventory (currently $27M) with ownership activity and broader fundamentals.

Neogenomics's inventory is $27M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.